No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Five-Fraction Stereotactic Body Radiotherapy was Noninferior to Control Radiotherapy in Biochemical or Clinical Failure in Localized Prostate Cancer

byJinny TsangandMinjee Kim

October 30, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

Stockholm3 outperforms PSA for detecting significant prostate cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

#VisualAbstract: A Liberal Transfusion Strategy is Superior to a Restrictive Strategy in Patients With Acute Brain Injury

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Oncology

Stockholm3 outperforms PSA for detecting significant prostate cancer

June 22, 2026

Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026

Radiographic surrogates may predict tumor-specific survival in renal carcinoma

Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors

Anti-TNF therapy for inflammatory bowel disease may induce skin lesions

Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares

Equivalent efficacy of Paclitaxel or Irinotecan for advanced gastric cancer

Astellas: Vyloy improves survival in patients with advanced gastric cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result